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Background: The main objective is to present health state utility estimates for a broad range of mental health
conditions including anxiety, depression, long-term depression, obsessive compulsive disorder, phobia, panic disorder,
psychosis, alcohol and drug dependency that can be used in economic models.
Methods: This study uses pooled data from the Adult Psychiatric Morbidity Surveys carried out in 2000 and 2007
of a representative sample of the general population in England. Health state utility values measured by the SF-6D and
EQ-5D indices are the dependent variables. Independent variables include background characteristics, mental health
and physical health conditions. Regression models were estimated using OLS for the SF-6D and tobit for EQ-5D. Further
regressions were carried out to consider the impact of mental health and physical health morbidities and the impact
of severity of conditions on utility values.
Results: Mental health conditions tend to have a larger impact on health state utility values than physical health
conditions. The mental health conditions associated with the highest decrements in utility are: depression, mixed anxiety
and depressive disorders and long-term depression. Interaction terms used to model the effect of co-morbidities
are generally found to be positive implying that simply adding the utility decrements for two mental health con-
ditions overestimates the burden of the disease.
Conclusions: This paper presents reliable and representative community based mean SF-6D and EQ-5D estimates
with standard errors for health state utility values across a broad range of mental health conditions that can be
used in cost effectiveness modelling.
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While the prevalence of mental health conditions is in-
creasing in the UK, there is a dearth of country specific
data on the impact of mental health conditions on
health-related quality of life (HRQoL). There are a num-
ber of European studies that investigate HRQoL decre-
ments as a result of mental health conditions but none
of these includes the UK [1-3]. The focus of many sur-
veys has been epidemiological in nature concentrating
on prevalence of mental health conditions. Health state
utility values (HSUVs) take the form of an index* Correspondence: d.keetharuth@sheffield.ac.uk
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reproduction in any medium, provided the orconstructed from an outcome measure normally an-
chored from zero to one to represent death and full
health respectively. They are normally used by decision-
makers to evaluate and compare cost-effectiveness of
various treatments. HSUVs are particularly scarce for
more complex conditions like psychosis, phobia and
panic disorder [4] and disutility associated with different
levels of severity.
Decision makers such as the National Institute for
Health and Care Excellence (NICE) in the UK recom-
mend that the results of economic evaluations in health-
care are presented in terms of quality adjusted life years
(QALYs) which are a composite measure of health re-
lated quality of life and life expectancy. The mostl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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QALY are generic preference-based measures of health,
such as the EQ-5D [5] and SF-6D [6].This paper seeks
to address the lack of available HSUVs associated with
mental health conditions by providing estimates that can
be used in economic evaluation from a representative
community based sample.
Another important feature of mental health conditions
is the common existence of co-morbidities, arising from
other mental health conditions as well as physical ones.
Understanding the impact of one condition on HSUVs
cannot be done in isolation, but only after controlling
for other health conditions. Previous studies of mental
health conditions have largely failed to do this. There are
several studies in the literature that highlight the lack of
consensus on how best to calculate HSUVs [7,8]. While
attempts have been made to calculate HSUVs for co-
morbid physical conditions [9], for example by adding or
multiplying the effects of separate conditions, there is
still overall very little empirical research on co-
morbidities for those with mental health conditions.
Aims of the study
This paper has three objectives: (i) to estimate the im-
pact of mental health disorders on quality of life in
England (ii) to compare and contrast the impact of
physical health and mental health co-morbidities on
quality of life (iii) to assess the impact of severity of de-
pression, anxiety, phobia and panic disorders on quality
of life.
Specifically we estimate the decrement associated with
various mental health disorders using the SF-6D and
EQ-5D indices from a representative sample of the UK
general population and controlling for a wide range of
background variables.
Methods
Data
We used health-related quality of life data and informa-
tion on health status collected in the Adult Psychiatric
Morbidity Survey (APMS) carried out in 2000 and 2007
[10,11]. This is a rigorously conducted general popula-
tion survey aiming to provide information on the preva-
lence of psychiatric conditions among people living in
Great Britain, as well as their associated social disabil-
ities and use of services. Each APMS recruited about
8,000 working age adults in private households. APMS is
unique in the UK for having data on a broad range of
conditions including common mental health disorders
like depression, anxiety and obsessive compulsive dis-
order, psychotic conditions, personality disorders and al-
cohol and drug dependence. They also contain general
health measures including the SF-12 health index, a
measure from which the SF-6D preference based utilityindex can be obtained [12]. There is also information
on socio-demographic data, education and employ-
ment, income and debt, accommodation and stressful
life events. While the 2000 survey covered England,
Wales and Scotland, APMS 2007 only interviewed
people in England so our analysis uses data for England
only.
In both years APMS interviews are conducted in two
stages. First, a computer assisted personal interview in
the respondents own home covering neurotic symp-
toms and disorders using the Clinical Interview Schedule
Revised (CIS-R) and screening items on personality dis-
order and psychosis. CIS-R is a structured interview that
has been standardised so that it can be administered by
social survey interviewers. It enquires about 14 common
neurotic symptoms allowing categorisation according to
ICD-10 criteria. CIS-R also measures the severity of the
condition and is widely used [13,14]. A second stage sam-
ple was chosen comprising respondents who satisfied
screening criteria for psychotic and personality disorder.
The second stage interviews were conducted by trained
psychologists using Schedules for Clinical Assessment
in Neuropsychiatry (SCAN) and Structured Clinical
Interview (SCID-II). In 2000 (2007) there were 8580
(7461) initial interviews, a response rate of 54 (57)%. At
the second stage there were 638 (630) interviews and a
response rate of 73 (74)%. Our analysis sample com-
prises 5688 individuals in 2000 and 5388 individuals in
2007. Data for 2000 and 2007 are pooled.
Measuring HSUVs
Two generic preference-based measures were derived
from the SF-12 data: SF-6D and the EQ-5D. The SF-6D
health utility index is derived from individual responses
to the SF-12, a generic health measure based on items
taken from the SF-36 health survey, a standardised ques-
tionnaire used to assess patient health [15]. Brazier and
Roberts [9] developed a preference based index for the
SF-12 using an algorithm estimated from standard gam-
ble valuations of a sample of SF-6D states obtained from
members of the UK general population [6]. The index
takes values that range from zero (equivalent to dead) to
one (full health).
The EQ-5D questionnaire consists of 5 simple ques-
tions on mobility, self-care, usual activities, pain and dis-
comfort, anxiety and depression. As raw data was not
collected from respondents using the EQ-5D question-
naire, EQ-5D scores have been generated through map-
ping from SF12 items using a response approach
mapping [16]. It is deemed important to present the util-
ities using the EQ-5D, since the former is the method
preferred by NICE in the reference case [17]. In the re-
sponse mapping approach, multinomial logistic regres-
sion is used to estimate the probability that a respondent
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the EQ-5D, using individual question responses from the
SF-12 as predictors. EQ-5D responses are predicted
using Monte Carlo simulation methods and UK tariffs
are then applied to the raw scores to generate the EQ-
5D index [5].
Measuring severity of conditions
It is often useful to know the severity of the condition,
as quality of life decrements and health care costs are
usually much higher for greater levels of morbidity. Each
condition is diagnosed via a set of four questions from
the CIS-R. For example in the case of anxiety these are:
(i) felt generally anxious/nervous/tense for 4 days or
more in the past seven days; (ii) in past seven days anx-
iety/nervousness/tension has been very unpleasant; (iii)
in the past seven days have felt any of the following
symptoms when anxious/nervous/tense (Racing heart,
sweating or shaking hands, feeling dizzy, difficulty get-
ting one’s breath, dry mouth, butterflies in stomach, nau-
sea or wanting to vomit); (iv) felt anxious/nervous tense
for more than three hours in total on any one of the past
seven days. Each question scores one if that symptom
was present, giving a total anxiety score ranging from
zero for no symptoms to four. This score can be used as
a measure of severity of the condition. A similar ap-
proach was taken with depression, panic and phobia.
Analysis
The basic model to be estimated is:
Ui ¼ f Mi;Pi;Xi;εi
  ð1Þ
Where Ui is health utility for respondent i; M is men-
tal health, P is physical health and X is a set of back-
ground characteristics, εi is a random error term.
Two separate sets of analyses are carried out with SF-
6D and EQ-5D as dependent variables. The initial mod-
elling was undertaken using Ordinary Least Squares
(OLS) but this can be criticised. OLS estimates are
biased and inconsistent, because both the SF-6D and
EQ-5D distributions are skewed and in addition the EQ-
5D distribution is truncated with many observations at
the upper value of one [18]. To overcome these prob-
lems, OLS models for SF-6D are estimated with robust
error variance as Breusch-Pagan/Cook-Weisberg tests
results suggest heteroskedastic errors, and for the EQ-
5D, tobit models are used to deal with the truncated na-
ture of the data.
Mental health (M) is measured by a set of dichotom-
ous variables to represent the presence of specific disor-
ders. Diagnosis of specific disorders were assigned by
the Office of National Statistics using answers to various
sections of the CIS-R and applying algorithms based onthe ICD-10 diagnostic criteria; these disorders are: gener-
alised anxiety disorder (GAD), mixed anxiety depressive
disorder (MADD), panic disorder, obsessive compulsive
disorder (OCD), phobia, and depression. Psychosis and
personality disorder are assigned via the Stage 1 screening
questions, alcohol dependence is defined according to the
Severity of Alcohol Dependence questionnaire (SAD-Q)
and drug dependence defined according to questions
used in the US Epidemiologic Catchment Area survey.
A variable was generated to represent people who self-
report that they have long-term depression lasting for a
period of 2 years or over [19]. More detail on defini-
tions for each disorder can be found in the APMS tech-
nical reports [10,11].
Physical health (P) is measured by a set of dichotom-
ous variables denoting the presence of self-reported
long-standing health conditions: muscular-skeletal, re-
spiratory, digestive, heart and circulatory, urinary, skin,
ear, eye, neoplasm, blood disorder, and infection. The set
of background variables (X) include age, marital status,
presence of children aged 16 or under in the household,
employment status, ethnicity, education and income.
Dummy variables for regions and year are also included.
A full list of variables and definitions can be obtained
from the corresponding author.
Although co-morbidities are an important issue for
cost-effectiveness modelling, there is no consensus about
the best method to estimate HSUVs for co-morbidities
[7]. To allow a flexible approach we have explored all
first order interactions between mental health conditions
and physical health conditions by estimating models (2)
and (3) below:
Ui ¼ f Mi;Pi;Xi;IMi; εi
  ð2Þ
Ui ¼ f Mi;Pi;Xi;IPi;εi
  ð3Þ
Where IM is a set of dichotomous variables representing
first order interactions between the seven mental health
conditions described above and IP is a set of dichotomous
variables representing first order interactions between the
seven mental health conditions and the seven physical
health conditions described above. It was not possible to
investigate co-morbidities for personality disorder, psych-
osis and panic due to the small number of observations.
In addition some physical conditions could not be consid-
ered due to small sample sizes, including ear complaints,
neoplasm, blood disorder and infectious disorder. Data
from the APMS was downloaded from the UK Data
Archive [20] and STATA 11 was used for the analysis.
Results
Table 1 reports descriptive statistics for the entire sam-
ple of 11080 cases. The distribution of the SF-6D health
Table 1 Descriptive statistics for entire sample
N %
Total sample 11080
Male 4893 44.2
Single 2405 21.7
Married 6796 61.3
widow/divorced/separated 1879 17.0
Children under 16 3786 34.2
Education- Degree 2151 19.4
Education- HND/Teach/Nursing 854 7.7
Education - A level 1680 15.2
Education - GCSE/O level 3048 27.5
Education - lower level 760 6.9
Education - none 2448 22.1
Gross personal income < £5200 p.a. 2218 20.0
Gross personal income 5200-10399 p.a. 2118 19.1
Gross personal income 10400 -15559 p.a. 1781 16.1
Gross personal income 15560 m-20799 p.a. 1278 11.5
Gross personal income 20800 -33799 p.a. 1885 17.0
Gross personal income >33800 p.a. 1074 9.7
Non white 1084 9.8
Working 7794 70.3
Mean Standard deviation
Age in years 42.7 12.8
SF-6D index 0.791 0.139
EQ-5D index 0.808 0.206
Table 2 Descriptive statistics: utility scores for people
with physical and mental health conditions
Physical health n % SF-6D
mean
SF-6D
sd
EQ-5D
mean
EQ-5D
sd
No physical health
problems
5879 53.1 0.829 0.114 0.851 0.165
Muscular/skeletal
complaint
2471 22.3 0.709 0.160 0.705 0.258
Respiratory complaint 969 8.7 0.726 0.159 0.740 0.254
Digestive complaint 606 5.5 0.706 0.163 0.710 0.261
Heart/circulatory complaint 1232 11.1 0.732 0.162 0.741 0.251
Urinary related complaint 588 5.3 0.689 0.159 0.696 0.276
Skin complaint 726 6.6 0.747 0.147 0.763 0.225
Ear complaint 434 3.9 0.737 0.154 0.752 0.247
Eye complaint 819 7.4 0.756 0.152 0.771 0.235
Neoplasm 117 1.1 0.689 0.160 0.710 0.261
Blood disorder 214 1.9 0.725 0.165 0.722 0.275
Infectious disorder 52 0.5 0.681 0.142 0.702 0.240
Mental health
No mental health
problems*
8263 74.6 0.827 0.114 0.842 0.170
Generalised anxiety
disorder
613 5.5 0.626 0.141 0.643 0.288
Mixed anxiety depressive
disorder
1098 9.9 0.657 0.131 0.681 0.258
Panic disorder 121 1.1 0.645 0.134 0.664 0.274
Obsessive compulsive
disorder
162 1.5 0.576 0.113 0.593 0.294
Phobia 267 2.4 0.573 0.114 0.577 0.297
Depression 367 3.3 0.551 0.105 0.537 0.311
Long-term depression 187 1.7 0.532 0.104 0.513 0.324
Psychosis 81 0.7 0.623 0.138 0.665 0.281
Personality disorder 31 0.3 0.648 0.153 0.706 0.274
Alcohol dependency (any) 781 7.0 0.761 0.144 0.790 0.222
Drug dependency 379 3.4 0.732 0.144 0.774 0.216
Neurotic symptoms score
cisr score_1 (0 - 5) 7146 64.5 0.848 0.100 0.861 0.152
cisr score_2 (6 - 11) 1954 17.6 0.744 0.126 0.774 0.205
cisr score_3 (12 -17) 957 8.6 0.679 0.125 0.712 0.237
cisr score_4 (18 -23) 489 4.4 0.617 0.125 0.636 0.273
cisr score_5 (24 –29) 282 2.5 0.572 0.112 0.576 0.291
cisr score_6 (30 –35) 161 1.5 0.542 0.098 0.536 0.306
cisr score_7 (36+) 91 0.8 0.518 0.099 0.464 0.338
*No mental health problem category includes a score of 11 or below on the
cis-r scale.
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the higher end of the scale (Additional file 1: Figure
S1a). However there is no obvious ceiling or floor effect
and only a small proportion of observations take the
value of one (less than 5%). While the mean scores for
SF-6D (0.791) and EQ-5D (0.808) are very similar, the
distributions are very different. The EQ-5D distribution
has a ceiling effect with 33% of observations at full
health. SF-6D and EQ-5D scores range between 0.35
and 1 and between -0.38 and 1 respectively (Additional
file 1: Figure S1b).
Table 2 shows the descriptive statistics on physical and
mental health conditions with mean utility scores.
Around 82% of people in this dataset have no mental
health disorder, similar to the prevalence rate reported
in the APMS reports [10,11]. The most common prob-
lem is Mixed Anxiety Depressive disorder (MADD)
found in around 10% of respondents, and this is
followed by alcohol dependency, which is here defined
as any level of dependency detected by the SADQ, ran-
ging from mild to severe. The SF-6D (EQ-5D) scores for
those with no physical health problem and no mentalproblem are 0.829 (0.851) and 0.827 (0.842) respectively.
All the scores for the EQ-5D are marginally higher than
the SF-6D. Long-term depression and depression suf-
ferers have the lowest SF-6D (EQ-5D) scores of 0.532
Table 3 Health decrements in SF-6D and EQ-5D scores
SF-6D
(OLS regression)
EQ-5D
(Tobit regression)
Coefficient SE Coefficient SE
male 0.011 *** 0.002 0.015 *** 0.004
age -0.005 *** 0.001 -0.002 ** 0.001
Mental health conditions
Generalised anxiety
disorder
-0.086 *** 0.006 -0.070 *** 0.009
Mixed anxiety
depressive disorder
-0.136 *** 0.004 -0.127 *** 0.007
Panic disorder -0.077 *** 0.012 -0.076 *** 0.019
Obsessive compulsive
disorder
-0.057 *** 0.011 -0.034 ** 0.016
Phobia -0.083 *** 0.008 -0.081 *** 0.015
Depression -0.137 *** 0.007 -0.159 *** 0.014
Long-term depression -0.100 *** 0.01 -0.118 *** 0.019
Psychosis -0.001 0.011 0.017 0.02
Personality disorder -0.010 0.024 0.013 0.032
Alcohol dependency
(any)
-0.002 0.004 0.006 0.007
Drug dependency -0.027 *** 0.006 -0.011 0.01
Physical health conditions
Muscular/skeletal
complaint
-0.071 *** 0.003 -0.093 *** 0.005
Respiratory complaint -0.029 *** 0.004 -0.025 *** 0.007
Digestive complaint -0.030 *** 0.005 -0.032 *** 0.008
Heart/circulatory
complaint
-0.028 *** 0.004 -0.025 *** 0.006
Urinary related
complaint
-0.040 *** 0.005 -0.037 *** 0.009
Skin complaint -0.016 *** 0.004 -0.019 ** 0.008
Ear complaint -0.028 *** 0.006 -0.016 0.01
Eye complaint -0.006 0.004 -0.004 0.007
Neoplasm -0.054 *** 0.012 -0.046 ** 0.019
Blood disorder -0.034 *** 0.009 -0.039 *** 0.015
Infectious disorder -0.050 *** 0.018 -0.037 0.028
Constant 0.881 *** 0.013
Observations 10,289
R-squared/Pseudo R-
squared
0.413 0.252
Reset test (omitted
variables)
79.07 ***
Pregibon link test
(model specification)
0.348 *** 0.084 0.108
Chi-square 2153 ***
Note: Socio-demographics variables including education, income level, ethni-
city, working status and regions have been controlled for in the model but are
not reported here. ***p < 0.01, **p < 0.05, *p < 0.1.
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neurotic symptoms score, those with more severe symp-
toms have monotonically lower utility scores as mea-
sured by both SF-6D and EQ-5D.
The results from the OLS and tobit regressions for
SF-6D and EQ-5D respectively are shown in Table 3.
Marginal effects have been calculated at the means of
the explanatory variables for tobit regressions. The
highest decrements in HSUVs are observed for depres-
sion, MADD, long-term depression and GAD for both
SF-6D and EQ-5D. The HSUV decrements in SF-6D
(EQ-5D) scores are as follow: depression -0.137
(-0.159); MADD -0.136 (-0.127); long-term depression
-0.100 (-0.118); GAD -0.086 (-0.070); phobia -0.083
(-0.081); panic -0.077 (-0.076); OCD -0.057 (-0.034)
and; drug dependency -0.027 (-0.011). The three mental
health conditions that do not have a statistically signifi-
cant effect on health utility are psychosis, personality
disorder and alcohol dependence. The coefficients for
psychosis and personality disorder may be insignificant
due to the small numbers of people (81 and 31 respect-
ively) suffering from these conditions. All of the phys-
ical health conditions, except eye complaints, are
statistically significant at 1% level of significance. In the
models for both SF-6D and EQ-5D, socio-demographic
characteristics were controlled for. They are not re-
ported in this paper but are available by request from
authors.
For the OLS regression for SF-6D, the adjusted R2 is
0.41 but the Ramsey Regression Equation Specification
Error Test (RESET) [21] and Pregibon [22] link test sta-
tistics suggest that the model suffers from omitted vari-
ables and misspecification problems respectively. It is
worth noting that these tests also revealed misspecifica-
tion problems with both tobit [23] and Postestimation
Generalized Linear Models (PGLM) models [24,25]
which were also explored for the SF-6D (not reported
here). The marginal effects of physical and mental health
conditions on the SF-6D index are very similar regard-
less of the estimation procedure and functional form
chosen, a finding similar to that of Jones [26] who com-
pared a number of different models for modelling health
care cost data. In the case of EQ-5D as the dependent
variable, the link test suggests that the model is correctly
specified making tobit regression a better model than
OLS in this case.
Co-morbid Health Conditions
Table 4 reports the results for the models exploring in-
teractions between mental health conditions. Only the
coefficients on the main mental health conditions and
the significant (at p = 0.05) interactions are reported.
The coefficients on the mental health conditions are dif-
ferent compared to Table 3 but remain statistically
Table 4 Utility values for mental health co-morbidities:
SF6 and EQ-5D scores
SF 6D OLS models EQ-5D tobit models
N Coefficient se Coefficient se
Generalised
anxiety disorder
-0.094 *** 0.006 -0.081 *** 0.010
OCD -0.099 *** 0.012 -0.091 *** 0.023
GAD X OCD 70 0.103 *** 0.019 0.097 *** 0.019
Generalised
anxiety disorder
-0.101 *** 0.006 -0.081 *** 0.010
Phobia -0.133 *** 0.010 -0.115 *** 0.019
GAD X Phobia 124 0.121 *** 0.015 0.063 *** 0.019
Generalised
anxiety disorder
-0.107 *** 0.006 -0.086 *** 0.011
Depression -0.182 *** 0.007 -0.195 *** 0.018
GAD X
Depression
162 0.122 *** 0.013 0.068 *** 0.016
Generalised
anxiety disorder
-0.094 *** 0.006 -0.078 *** 0.000
Alcohol
Dependency
-0.008 * 0.051 -0.0001 0.008
GAD X Alcohol
Dependency
90 0.057 *** 0.015 0.050 *** 0.018
Generalised
anxiety disorder
-0.090 *** 0.006 -0.076 *** 0.010
Drug
Dependency
-0.033 *** 0.006 -0.019 * 0.011
GAD X Drug
Dependency
48 0.057 *** 0.021 0.064 *** 0.023
MADD -0.138 *** 0.004 -0.132 *** 0.008
Alcohol
Dependency
-0.006 0.004 -0.001 0.008
MADD X Alcohol
dependency
111 0.024 * 0.012 0.044 *** 0.017
OCD -0.096 *** 0.012 -0.072 *** 0.021
Phobia -0.105 *** 0.009 -0.102 *** 0.016
OCD X Phobia 56 0.133 *** 0.020 0.091 *** 0.021
OCD -0.110 *** 0.013 -0.096 *** 0.024
Depression -0.155 *** 0.007 -0.181 *** 0.015
OCD X
Depression
78 0.127 *** 0.019 0.101 *** 0.018
Phobia -0.127 *** 0.010 -0.090 *** 0.018
Depression -0.165 *** 0.008 -0.165 *** 0.016
Phobia X
Depression
111 0.126 *** 0.016 0.023 0.023
Depression -0.144 *** 0.007 -0.151 *** 0.015
Alcohol
Dependency
-0.005 0.004 0.009 0.007
Depression X
Alcohol
Dependency
73 0.040 ** 0.017 -0.040 0.028
***p < 0.01, **p < 0.05, *p < 0.1.
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cients on all of the interaction terms are positive
implying that having both conditions results in a
health utility decrement that is less than the sum of
the individual coefficients. For example, having GAD and
depression, the decrement to the SF-6D index is -0.107 -
0.182 + 0.122 = -0.167; this is smaller than that sug-
gested by the additive model of -0.289. In this case it
is also highlighted that the interaction term more than
offsets the main effects of GAD. Similarly using EQ-
5D, the decrement associated with GAD and depres-
sion is -0.213. Despite the insignificant main effects
for alcohol dependence, there are significant positive
interactions with GAD, MADD (EQ-5D only) and
depression.
Table 5 reports the results to explore interactions with
physical conditions; only for models where the coeffi-
cients on the main health conditions and the interac-
tions are significant (at p = 0.05). The coefficients on the
mental and physical health conditions are similar to
those in Table 3 and are statistically significant. Of the
interactions reported, the majority are positive, meaning
that the presence of both disorders reduces health utility
by a smaller amount than that suggested by the additive
model. The only interaction terms that are negative are
MADD and respiratory complaints, and MADD and
muscular skeletal complications with the latter inter-
action being insignificant.
Severity of mental health condition
We have explored the severity of four conditions: de-
pression (n = 367), anxiety (n = 613), phobia (n = 267)
and panic (n = 121). We estimate model (1) and in the
vector M, the dichotomous variable for the presence of
anxiety (depression) is replaced with a set of four
dummy variables indicating the score, compared to a
baseline of zero. The results are shown in Table 6; the
effect on other coefficients is negligible so only the esti-
mated coefficients on the new set of dummy variables
are reported. The results for depression are as expected,
the utility decrement increases with the severity of the
condition.
For anxiety, while there is a gradient overall from level
1 to 4, the estimated coefficient for levels 3 and 4 have
very similar decrements. In this case, the levels have
been aggregated to represent only two severity levels
with the more severe level showing a higher SF-6D
(EQ-5D) decrement of -0.070 (-0.068) compared with
the lower severe level of -0.047 (-0.032).
The severity levels for phobia and panic have also been
aggregated to distinguish between two severity levels. In
the case of phobia, higher decrements are observed in
both SF-6D and EQ-5D scores for the more severe
levels. It is noted that the EQ-5D scores are not
Table 5 Utility values for mental health and physical health co-morbidities: SF6 and EQ-5D scores
SF 6 OLS models EQ-5D tobit models
N Coefficient se Coefficient se
Generalised anxiety disorder -0.095 *** 0.006 -0.077 *** 0.012
Muscular/skeletal complaint -0.073 *** 0.003 -0.094 *** 0.005
GAD X muscular/skeletal 233 0.025 ** 0.011 0.015 0.015
Generalised anxiety disorder -0.090 *** 0.006 -0.075 *** 0.010
Digestive complaint -0.034 *** 0.006 -0.036 *** 0.009
GAD X digestive complaint 74 0.034 * 0.017 0.03 0.021
Generalised anxiety disorder -0.091 *** 0.006 -0.071 *** 0.010
Urinary complaint -0.044 *** 0.006 -0.038 *** 0.009
GAD X Urinary complaint 75 0.039 *** 0.018 0.008 0.023
Generalised anxiety disorder -0.091 0.006 -0.079 *** 0.010
Eye complaint -0.009 ** 0.004 -0.009 0.007
GAD X eye complaint 71 0.039 ** 0.018 0.06 *** 0.019
MADD -0.133 *** 0.004 -0.125 *** 0.008
Respiratory complaint -0.025 *** 0.004 -0.023 *** 0.007
MADD X respiratory complaint 150 -0.025 ** 0.010 -0.013 0.017
MADD -0.139 *** 0.004 -0.126 *** 0.007
Urinary complaint -0.045 *** 0.006 -0.035 *** 0.010
MADD X Urinary complaint 113 0.028 ** 0.013 -0.009 0.020
MADD -0.139 *** 0.004 -0.132 *** 0.007
Skin complaint -0.020 *** 0.005 -0.027 *** 0.008
MADD X skin complaint 97 0.031 ** 0.013 0.049 *** 0.018
MADD -0.136 *** 0.004 -0.121 *** 0.009
Muscular/skeletal complaint -0.071 *** 0.003 -0.090 *** 0.005
MADD X muscular/skeletal 369 -0.001 0.008 -0.016 0.013
Depression -0.154 *** 0.008 -0.188 *** 0.017
Muscular/skeletal complaint -0.073 *** 0.003 -0.096 *** 0.005
Depression X muscular/ skeletal 127 0.053 *** 0.013 0.062 *** 0.016
Depression -0.147 *** 0.007 -0.166 *** 0.015
Respiratory complaint -0.032 *** 0.004 -0.027 *** 0.007
Depression X respiratory complaint 63 0.060 *** 0.016 0.032 0.023
Depression -0.143 *** 0.007 -0.164 *** 0.015
Urinary complaint -0.043 *** 0.006 -0.040 *** 0.009
Depression X Urinary complaint 57 0.039 * 0.006 0.030 0.025
Phobia -0.097 *** 0.009 -0.086 *** 0.018
Muscular/skeletal complaint -0.072 *** 0.003 -0.093 *** 0.005
Phobia X muscular/skeletal 100 0.038 ** 0.016 0.012 0.022
Alcohol dependency -0.007 0.004 0.0001 0.008
Muscular/skeletal complaint -0.072 *** 0.003 -0.095 *** 0.005
Alcohol dependency X muscular/skeletal 176 0.019 * 0.011 0.024 0.015
***p < 0.01, **p < 0.05, *p < 0.1.
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EQ-5D show a lower decrement for the more severe
level and only the SF6D value is significant. This ispossibly mainly due the fact that there are only 57 and
64 individuals in the less severe and more severe cat-
egories respectively.
Table 6 Impact of severity of Anxiety, Depression, Phobia and Panic on SF-6D and EQ-5D scores
Depression (n = 367 with depression present)
Score 1 n = 1047 Score 2 n = 75 Score 3 n = 219 Score 4 n = 73
SF6 – coefficient -0.062*** -0.084*** -0.127*** -0.149***
SF6 – standard error 0.004 0.005 0.006 0.010
EQ-5D – coefficient -0.052*** -0.069*** -0.120*** -0.177***
EQ-5D– standard error 0.007 0.009 0.011 0.021
Anxiety (n = 613 with anxiety present)
Score 1 n = 277 Score 2 n = 336
SF6 – coefficient -0.047*** -0.070***
SF6 – standard error 0.003 0.006
EQ-5D – coefficient -0.032*** -0.068***
EQ-5D– standard error 0.006 0.012
Phobia (n = 267 with phobia present)
Score 1 n = 139 Score 2 n = 138
SF6 – coefficient -0.017*** -0.039***
SF6 – standard error 0.004 0.005
EQ-5D – coefficient -0.010 -0.012
EQ-5D– standard error 0.007 0.010
Panic (n = 121 with panic present)
Score 1 n = 57 Score 2 n = 64
SF6 – coefficient -0.040*** -0.037
SF6 – standard error 0.011 0.01
EQ-5D – coefficient -0.015 -0.024
EQ-5D– standard error 0.019 0.016
***p < 0.01, **p < 0.05, *p < 0.1. "*" refers to p<0.1 or 10% significance level.
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Our estimates from over 10,000 responses to the APMS
2000 and 2007 show that all but three of the mental
health conditions considered here have a statistically sig-
nificant and relatively large adverse effect on health util-
ity measured by both SF-6D and EQ-5D indices. These
effects are larger than for self-reported physical health
conditions. Another study also found that HRQoL dec-
rements from mental health conditions are higher than
those reported by suffers of chronic physical conditions
[1]. Depression, MADD and GAD are the mental health
conditions that impact most on health. The three mental
health conditions that are not statistically significant are
alcohol dependency, personality disorder and psychosis.
In considering co-morbidities, we have used interaction
terms and in most cases they are significant confirming
the fact that we cannot simply add HSUVs decrement of
co-morbid health conditions. The impact on HSUVs is
generally less than the addition of the separate health
conditions. When considering interactions between
mental and physical health conditions, the majority are
positive, however in one case the interaction is negative
and significant suggesting that the presence of bothconditions reduces health utility by a larger amount that
the additive model would suggest. Brief exploration of
the effects of the severity of anxiety and depression on
the health utility index, suggest that for depression the
results are as expected, the utility decrement increasing
with the severity of the condition. However, for anxiety,
panic and phobia, only two severity levels were
considered.
Utility decrements have been measured using both SF-
6D and EQ-5D predicted using a published mapping
function. Both measures on the whole depict a similar
picture. In general, for most physical and mental health
conditions, the decrements shown by SF-6D and EQ-5D
are similar and this finding is supported by a study com-
paring SF-6D and EQ-5D across seven patient groups
with physical health conditions [27]. A multi-centre ran-
domised control trial in Netherlands [28] found that
EQ-5D utilities led to significant higher health gains
even though EQ-5D mean scores were lower than SF-6D
scores at baseline. A study on patients with schizophre-
nia revealed similar EQ-5D and SF-6D mean scores at
baseline but higher EQ-5D mean scores higher at
follow-up [29].
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are statistically insignificant. This finding is line with a
recent review where it was found that SF-6D and EQ-5D
are inadequate measures for such conditions [30]. Simi-
larly, the insignificant coefficient for psychosis is in line
with the finding that generic measures are not suitable
for use in schizophrenia, a psychotic disorder [31]. An
additional reason why personality disorder and psychosis
are not statistically significant could be due to relatively
small numbers, as less than 1% of the sample has these
conditions. For alcohol dependency we explored whether
the insignificant result was due to our relatively broad
definition of any dependency, by testing the effects of
moderate and severe dependence on alcohol (as defined
by the SADQ) alone, but these were not statistically sig-
nificant either. Another study found that alcohol de-
pendence was insignificant but similar to this paper, it
was not possible to understand how and why this was
the case [1].
The effects of co-morbidities are investigated through
interaction terms. For the majority of mental health co-
morbidities, the interaction terms are positive and often
offset the decrement caused by a single condition. While
it is understandable that this may be the case, clinically
it is difficult to explain. It may be that patients get better
at managing their conditions having been exposed to an-
other mental health condition. In the presence of a men-
tal health condition and a physical health condition,
some of the results are very surprising. First, several of
the interaction terms as measured by EQ-5D score are
statistically insignificant even though the both main ef-
fects are statistically significant. These include GAD and
muscular/skeletal complaints, GAD and digestive com-
plaint, GAD and urinary complaints, MADD and urinary
complaints, MADD and skin complaints, depression and
respiratory complaints, phobia and muscular/skeletal
complaints. This is not the case when the dependent
variable is SF-6D. It may be due to the artefact of the
mapping approach. In some cases, the main effects are
not statistically significant but the interaction terms are.
Examples include alcohol dependency and digestive
complaints, where alcohol dependency is insignificant
but the interaction term is significant. In this case, it is
not clear whether it is acceptable to use the HSUVs thus
generated. A possible explanation for the latter result is
the fact that alcohol may be used to alleviate the symp-
toms of GAD and MADD.
Limitations
Overall the models we have estimated have good ex-
planatory power but the RESET test does suggest mis-
specification problems. We have explored both tobit and
generalised linear models for the SF-6D but these were
still wrongly specified. The EQ-5D index also suffersfrom ceiling effects and therefore more sophisticated
models may be used to address that. Despite the weak-
nesses of OLS regressions in the case of SF-6D, it was de-
cided to present the results as they are easy to interpret
and in the absence of better estimates, those generated in
this paper can be readily used in decision-analytic models.
It is worth stressing here that the data we have used to
estimate these models is not based on clinical diagnosis
of mental health conditions, but instead on well-
established instruments administered by trained inter-
viewers. Furthermore, while data on the mental health
conditions are reliable, the data on physical conditions
are self-reported and are therefore less reliable since
there was no confirmation of the conditions. Finally, the
data is limited to those living in private households,
though this accounts for the vast majority of people with
these conditions.
There may also be a concern as to whether a generic
measure of health like the SF-12 adequately assesses the
impact of all mental disorders – particularly personality
disorders and psychosis. The other limitation is that the
EQ-5D estimates are based on a mapping function that
been shown to have a tendency to underestimate values
at the upper end of the scale and overestimate values at
the lower end. Other mapping functions have not over-
come this limitation and it may result in an underesti-
mate of the impact of different conditions [32].
Conclusions
Despite these limitations, this study has a number of in-
teresting findings. First, the estimates provided are based
on a representative sample of the UK population. Gener-
ally HSUV are generated from trial data and there are al-
ways questions as to whether they can be generalised
and used outside the trial setting. Therefore the decre-
ments associated with the various mental health condi-
tions and co-morbidities in this paper can be readily
used in decision-analytic models in assessing cost-
effectiveness of health technologies. Second the APMS is
regarded as the most reliable available data in the UK in
the area of mental health.
There are several implications of this paper. First,
background characteristics need to be controlled for
when estimating HSUVs. This is very important but
often not accounted in single condition studies. As a re-
sult the HSUV decrement associated with a particular
health condition is possibly higher which, in turn has
implications in cost-effectiveness analysis. Second, the
paper has also been able to generate estimates for
HSUVs associated with long-term depression. Third, the
paper shows that simply adding HSUVs for co-morbid
health conditions is not appropriate. Fourth, it provides
decrements that can be used to reflect severity of the
following conditions: depression, anxiety, panic and
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http://www.hqlo.com/content/12/1/6phobia. These are useful parameters that can be used in
decision analytic models where conditions of patients
may be shown to progress.
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